US › Healthcare

ProQR Therapeutics BV (PRQR)

US · Healthcare · Biotechnology

$1.89+1.61%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$8.9M

Revenue YoY

+133.3%

Net profit

$-8.9M

EPS

$-0.10

EPS estimate

$-0.14

Net margin

-99.6%

EPS came in at -0.10 against a street estimate of -0.14 — a beat of 28.6%.

Key statistics

Market cap

$262.5M

Forward P/E

0.0

P/B

2.84

Book value

$0.84

EPS (TTM)

$-0.47

52-week high

$3.10

52-week low

$1.33

50-day MA

$1.93

200-day MA

$1.78

Beta

0.06

Analyst view

Analysts rate ProQR Therapeutics BV a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $8.22.

Shareholding

Insiders

17.16%

Institutions

54.50%

Largest institutional holders

Fund	Stake
Adage Capital Partners Gp LLC	6.39%
Aberdeen Group PLC	6.33%
Affinity Asset Advisors, LLC	3.93%
Privium Fund Management B.V.	3.87%
Kynam Capital Management, LP	1.11%
Dafna Capital Management LLC	1.08%
Squadron Capital Management LLC	1.07%
Ikarian Capital, LLC	1.06%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ProQR Therapeutics BV — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.